LncRNA Lnc712 Promotes Tumorigenesis in Hepatocellular Carcinoma by Targeting MiR-142-3p/Bach-1 Axis

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Nov 12

PMID 33177878

Citations 9

Authors

Dan Cui

Caifang Ni

Affiliations

Soon will be listed here.

Abstract

Background: It is known that Lnc712 plays an important role in the pathogenesis of breast cancer. However, whether it is involved in hepatocellular carcinoma (HCC) remains unknown. In this study, we aimed to investigate the role and underlying mechanism of Lnc712 in HCC.

Methods: Sixty-four HCC patients were enrolled and followed up for 5 years to analyze the prognostic value of Lnc712 for HCC. HCC cells were transfected with Lnc712 expression vector, Bach-1 expression vector (or siRNA) and miR-142-3p mimic (or inhibitor) to explore the interactions among Lnc712, miR-142-3p and Bach-1. Cell proliferation, migration, invasion and cell cycle were analyzed by CCK-8 assay, transwell assay, wound healing assay and flow cytometry assay, respectively.

Results: The expression of Lnc712 was upregulated in HCC, and the upregulated Lnc712 expression was significantly related to poor overall survival in HCC patients. In HCC cells, Lnc712 interacted with miR-142-3p and upregulated Bach-1, a target of miR-142-3p. In addition, Lnc712 promoted HCC cell proliferation, migration, invasion and cell cycle, while its effects were abolished by miR-142-3p mimic. Moreover, miR-142-3p mimic enhanced HCC cell proliferation, migration, invasion and cell cycle, while its effects were abolished by Bach-1 overexpression. miR-142-3p inhibitor repressed cell proliferation, migration, invasion and cell cycle in HCC cells, while its effects were abolished by Bach-1 knockdown. Furthermore, Lnc712 knockdown remarkably inhibited HCC tumor growth in nude mice.

Conclusion: Lnc712 may promote the development of HCC by targeting the miR-142-3p/Bach-1 axis.

Citing Articles

Exploring the potential of asparagine restriction in solid cancer treatment: recent discoveries, therapeutic implications, and challenges.

Fontes M, Silva C, Roldan W, Monteiro G Med Oncol. 2024; 41(7):176.

PMID: 38879707 DOI: 10.1007/s12032-024-02424-3.

Transcription factor BACH1 in cancer: roles, mechanisms, and prospects for targeted therapy.

Hu D, Zhang Z, Luo X, Li S, Jiang J, Zhang J Biomark Res. 2024; 12(1):21.

PMID: 38321558 PMC: 10848553. DOI: 10.1186/s40364-024-00570-4.

Pathophysiological role of BACH transcription factors in digestive system diseases.

Song Q, Mao X, Jing M, Fu Y, Yan W Front Physiol. 2023; 14:1121353.

PMID: 37228820 PMC: 10203417. DOI: 10.3389/fphys.2023.1121353.

Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches.

Jesenko T, Brezar S, Cemazar M, Biasin A, Tierno D, Scaggiante B Pharmaceutics. 2023; 15(4).

PMID: 37111734 PMC: 10145575. DOI: 10.3390/pharmaceutics15041249.

ST8SIA6-AS1 contributes to hepatocellular carcinoma progression by targeting miR-142-3p/HMGA1 axis.

Feng T, Yao Y, Luo L, Zou H, Xiang G, Wei L Sci Rep. 2023; 13(1):650.

PMID: 36635290 PMC: 9837176. DOI: 10.1038/s41598-022-26643-8.

References

Davudian S, Mansoori B, Shajari N, Mohammadi A, Baradaran B . BACH1, the master regulator gene: A novel candidate target for cancer therapy. Gene. 2016; 588(1):30-7. DOI: 10.1016/j.gene.2016.04.040. View

Muhammad N, Steele R, Isbell T, Philips N, Ray R . Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death. Oncotarget. 2017; 8(39):66226-66236. PMC: 5630406. DOI: 10.18632/oncotarget.19887. View

Liang Y, Wu H, Lei R, Chong R, Wei Y, Lu X . Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem. 2012; 287(40):33533-44. PMC: 3460454. DOI: 10.1074/jbc.M112.392332. View

Bhattacharya S, Muhammad N, Steele R, Peng G, Ray R . Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth. Oncotarget. 2016; 7(22):33202-9. PMC: 5078086. DOI: 10.18632/oncotarget.8898. View

Balogh J, Victor 3rd D, Asham E, Burroughs S, Boktour M, Saharia A . Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016; 3:41-53. PMC: 5063561. DOI: 10.2147/JHC.S61146. View

Axley P, Ahmed Z, Ravi S, Singal A . Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018; 6(1):79-84. PMC: 5863002. DOI: 10.14218/JCTH.2017.00067. View

Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M . Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017; 67(2):302-309. DOI: 10.1016/j.jhep.2017.03.011. View

Sawyers C . Targeted cancer therapy. Nature. 2004; 432(7015):294-7. DOI: 10.1038/nature03095. View

Bhattacharya S, Muhammad N, Steele R, Kornbluth J, Ray R . Bitter Melon Enhances Natural Killer-Mediated Toxicity against Head and Neck Cancer Cells. Cancer Prev Res (Phila). 2017; 10(6):337-344. PMC: 5499682. DOI: 10.1158/1940-6207.CAPR-17-0046. View

10.

Cui Y, Lu C, Zhang Z, Mao A, Feng L, Fu L . A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation. Int J Biol Sci. 2020; 16(1):162-171. PMC: 6930380. DOI: 10.7150/ijbs.36429. View

11.

Petrick J, Kelly S, Altekruse S, McGlynn K, Rosenberg P . Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol. 2016; 34(15):1787-94. PMC: 4966339. DOI: 10.1200/JCO.2015.64.7412. View

12.

Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q . A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 2019; 18(1):28. PMC: 6381672. DOI: 10.1186/s12943-019-0957-7. View

13.

Zhu K, Zhang Z, Zhang H, Wang Z, Wang F . MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells. Artif Cells Nanomed Biotechnol. 2020; 48(1):415-424. DOI: 10.1080/21691401.2019.1652629. View

14.

Zhang L, Wang L, Wang Y, Chen T, Liu R, Yang W . LncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis. Biomed Pharmacother. 2018; 109:1140-1147. DOI: 10.1016/j.biopha.2018.10.105. View

15.

Ishaque T, Massie A, Bowring M, Haugen C, Ruck J, Halpern S . Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change. Am J Transplant. 2018; 19(2):564-572. PMC: 6349527. DOI: 10.1111/ajt.15144. View

16.

Wan D, Shen S, Fu S, Preston B, Brandon C, He S . miR-203 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC. Anticancer Agents Med Chem. 2015; 16(4):414-23. DOI: 10.2174/1871520615666150716105955. View

17.

Singh S, Chouhan S, Mohammad N, Bhat M . Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3. FEBS Lett. 2017; 591(10):1371-1382. DOI: 10.1002/1873-3468.12655. View

18.

Yin Z, Ma T, Yan J, Shi N, Zhang C, Lu X . LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway. J Cell Physiol. 2019; 234(10):18825-18836. DOI: 10.1002/jcp.28521. View

19.

Mansoori B, Mohammadi A, Ghasabi M, Shirjang S, Dehghan R, Montazeri V . miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. J Cell Physiol. 2018; 234(6):9816-9825. DOI: 10.1002/jcp.27670. View

20.

Levrero M, Zucman-Rossi J . Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016; 64(1 Suppl):S84-S101. DOI: 10.1016/j.jhep.2016.02.021. View